IP Library Granted Patent US 12,377,041
Granted Patent B2
US 12,377,041 · App. 17/444,447 · Granted Aug 5, 2025

Compositions containing plant mucilage

Inventor: Peter Pham (Tomball, TX)
A61K8/9789A61K8/0208A61K8/34A61K8/345A61K8/58A61K8/9794A61K9/70A61K36/185A61K36/73A61K36/752A61K36/88A61K47/10A61K47/24A61P29/00A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,041
App. No.
17/444,447
Granted
Aug 5, 2025
Kind
B2
Abstract

A body lubricating, moisturizing, anti-inflammatory, and anti-pain formulation utilizes a mucilage-containing extract derived from a plant such as okra, Abelmoschus esculentus ( Hibiscus esculentus ). The formulation can be provided as a free liquid such as a solution, suspension, foam, gel, cream, ointment, or spray or alternatively impregnated into an absorbent solid article such as a mask, a wipe, swab, a bandage, cloth pad or a gauze. Application of the formulation to a mucosal or external bodily tissue result in the application of a layer of mucilage that lubricates and moisturizes the tissue as well as protects it from external damage from foreign particles and UV irradiation. Application of the formulation to an inflamed tissue provides anti-inflammatory effects and relieves pain.

Claims (34)

1. A formulation for treating inflammation in a bodily tissue comprising:

a mucilage extracted from Abelmoschus , wherein said mucilage is present in the formulation at a concentration of 0.001%-5.0% (w/v);

one or more emollients, wherein said emollients are selected from the group consisting of Aloe barbadensis leaf juice and glycerin; and

one or more antioxidants, wherein said antioxidants are selected from the group consisting of Rubus idaeus seed oil and Citrus unshiu peel extract;

wherein said formulation is intended to be applied to a bodily tissue selected from the group comprising external tissues and mucosal tissues, and said formulation treats inflammation in said bodily tissue.

2. The formulation of claim 1 , wherein the mucilage is extracted from Abelmoschus esculentus.

3. The formulation of claim 2 , wherein the mucilage is extracted from plant material selected from the group consisting of fresh plant material, frozen plant material, dried plant material, and powdered plant material.

4. The formulation of claim 3 , wherein the Abelmoschus esculentus mucilage is extracted from powdered okra.

5. The formulation of claim 1 , further comprising one or more surfactants.

6. The formulation of claim 5 , wherein the one or more surfactants are selected from the group consisting of disodium laureth sulfosuccinate, decyl glucoside, cetalkonium chloride, disodium cocoamphodiacetate, and glycerin.

7. The formulation of claim 1 , further comprising caffeine as an antioxidant; sodium phytate as a chelating agent; hydrolyzed soy protein as a moisturizer; ethylhexylglycerin as a conditioning agent and preservative; and phenoxyethanol as a preservative.

8. The formulation of claim 1 , wherein the formulation is provided in a form selected from the group consisting of a wipe; a swab; a bandage; a gauze; a suspension; a foam; a gel; and a spray.

9. The formulation of claim 8 wherein the formulation is a gel.

10. The formulation of claim 1 , wherein the formulation is buffered to a pH range of about 5.5 to 8.0.

11. The formulation of claim 10 , wherein the formulation is buffered to a pH of about 6.5.

12. The formulation of claim 10 , wherein the formulation is buffered with one of more salts selected from the list consisting of sodium chloride, sodium lactate, potassium chloride, and calcium chloride.

13. The formulation of claim 12 , wherein the formulation further comprises one or more cationic, anionic, nonionic, or amphoteric surfactants.

14. A formulation for treating pain in a bodily tissue comprising:

a mucilage extracted from Abelmoschus , wherein said mucilage is present in the formulation at a concentration of 0.001%-5.0% (w/v);

one or more emollients, wherein said emollients are selected from the group consisting of Aloe barbadensis leaf juice and glycerin; and

one or more antioxidants, wherein said antioxidants are selected from the group consisting of Rubus idaeus seed oil and Citrus unshiu peel extract;

wherein said formulation is intended to be applied to a bodily tissue selected from the group comprising external tissues and mucosal tissues, and said formulation treats pain in said bodily tissue.

15. The formulation of claim 14 wherein the formulation is an anti-pain formulation comprising Abelmoschus esculentus mucilage; Rubus idaeus seed oil; Citrus unshiu peel extract; Aloe barbadensis leaf juice; sodium phytate; phenoxyethanol; and ethylhexylglycerin; and wherein the formulation is buffered to a pH range of about 5.5 to 8.0.

16. The formulation of claim 14 wherein the formulation is a gel.

17. The formulation of claim 14 , wherein the formulation is provided in a form selected from the group consisting of a wipe; a swab; a bandage; a gauze; a suspension; a foam; a gel; and a spray.

18. A method of treating inflammation in a bodily tissue comprising:

preparing the formulation of claim 1 ; and

applying the formulation to the bodily tissue in need of inflammation treatment.

19. A method of treating pain in a bodily tissue comprising:

preparing the formulation of claim 14 ; and

applying the formulation to the bodily tissue in need of pain treatment.

20. A method of treating pain in a bodily tissue or an inflamed bodily tissue comprising:

applying to the bodily tissue in need of pain treatment or the inflamed bodily tissue a formulation comprising Abelmoschus esculentus mucilage; Rubus idaeus seed oil; Citrus unshiu peel extract; Aloe barbadensis leaf juice; disodium laureth sulfosuccinate; decyl glucoside; disodium cocoamphodiacetate; glycerin; caffeine; sodium phytate; hydrolyzed soy protein; phenoxyethanol; ethylhexylglycerin; sodium chloride; sodium lactate, potassium chloride, and calcium chloride; and wherein the formulation is buffered to about pH 6.5.

21. The method of claim 20 wherein the formulation is absorbed through the skin or mucosal membrane.

Continuity (4)
Continuation In Part 16727433 · Dec 26, 2019
Continuation 16175451 · Oct 30, 2018
Continuation 15087267 · Mar 31, 2016
Related Publication 20220016019A1 · Jan 20, 2022
References Cited (9)
CN 105192083A · 2015 [cited by applicant]
Liu, Wenting and Gong, Lan, “Anti-demodectic effects of okra eyelid patch in Demodex blepharitis compared with tea tree oil,” Experimental and Therapeutic Medicine 21: 338, 2021, DOI: 10.3892/etm.2021.9769, 8 pages. [cited by applicant]
Nigo, William OD, et al, “Speed Questionnaire,”1 page, Cornea, “Psychometric Properties and Validation of the Standard Patient Evaluation of Eye Dryness Questionnaire,” vol. 32, Issue 9, Sep. 2013, 5 pages. [cited by applicant]
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL “Ocular Surface Disease index (OSDI)”, 2 pages, https://www.supereyecare.com/resources/OSDI.pdf, Reliability and Validity of the Ocular Surface Disease Index… [cited by applicant]
Narayanan, Srihari, et al, “ZEST—Zocular Eyelid System Treatment—improves contact lens discomfort caused by MGD,” Optometry's Meeting, 2020, E-poster. [cited by applicant]
Schachter, Scott, ARVO 6741—B0265 (YR 2019), https://eyedropsdatabase.co.uk/images.documents/ZEST_ARVO_Study_2019.pdf, 1 page. [cited by applicant]
Extended European Search Report including the Supplementary European Search Report dated Dec. 2, 2019, Appl. No. 17776622.7, 14 pages. [cited by applicant]
European Search Opinion dated Nov. 15, 2019, Appl. No. EP 177766227, 2 pages. [cited by applicant]
European Communication dated Oct. 9, 2020, Appl. No. 17776622.7, 4 pages. [cited by applicant]